

**Supplementary Figure 1.** Screening and randomization. From the 4,257 men who were assessed for eligibility, 3,835 were excluded: 3,789 were seronegative on recruitment, 22 withdrew from study, and 24 did not return for follow-up visit. A total of 422 men formed the primary cohort (68 received oral zinc+vitamin C, 67 oral hydroxychloroquine, 99 oral ivermectin, 107 povidone-iodine throat spray, and 81 oral vitamin C).



## **Supplementary Figure 2.**



1.0M 76.3 44.3 0.038 1.00 CD4 CD8 DP T cells 106 CD3+ T cells 10<sup>6</sup> 800 K 600 K **Ч-ОХ 5** 400 К G CD19+ B cells CD4 CD8 **DN T cells** CD45+ 200K Lymphocytes 11.6 7.53 47.2 . 10<sup>6</sup> 106 ...4 105 10<sup>4</sup> 10<sup>5</sup> 0 CD45 CD19 CD3 Gate: CD45+ Lymphocytes CD45+ Lymphocytes CD45+ Lymphocytes 34.4 CD8+ cytotoxic 36.8 66.6 9.79 Natural killer T cells 39.6 41.9 CD4+ helper T cells T cells cD3 cD ñ Natural killer cells 1.73 3.64 16.8 6.82 CD4 10<sup>4</sup> CD8 105 105 10<sup>5</sup> 106 10<sup>4</sup> CD56 106 0 Gate:Ungate CD14+Monocytes AND CD4dimCD3-Ungate 10<sup>6</sup> \_ 0.98 Non-classical 6.34 Intermediate Monocytes Monocytes 800K 4.91 CD14+ Monocytes SSC-A CD16 G CD4dim CD3 200 K Classical 0 -0.37 92.3 Monocytes

10<sup>4</sup>

CD4

0

. 10<sup>5</sup>

10<sup>6</sup>

CD45+ Lymphocytes

CD3+ T cells

104

CD14

10<sup>5</sup>

в

85.5

0.81

10<sup>6</sup>

Gate:Ungate

1.1

0

104

CD14

10<sup>3</sup>

106

107

10<sup>5</sup>

